Digest Network Come funziona
Network
/
Società
Qu
Non verificato

Quince Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

38 comunicati stampa

Guarda tutti i comunicati
09/02/2026
Mercato del lavoro
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/12/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/12/2025
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Eventi
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Quince Therapeutics to Participate at Investor Events in December 2025
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Industria
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/09/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
Fonte
Quince Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0